Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase A2 group IIE (PLA2G2E)
- Target
- PLA2G2E
- Molecular classification
- Enzyme, Secreted phospholipase A2 family, Calcium-dependent phospholipase, Lipolytic enzyme
01
Overview
Phospholipase A2 group IIE (PLA2G2E) is a calcium-dependent, secreted enzyme of the *secretory phospholipase A2* (sPLA2) family. It hydrolyzes the sn-2 position of membrane glycerophospholipids, generating free fatty acids (such as arachidonic acid) and lysophospholipids. PLA2G2E is expressed in human and murine tissues including skin, hair follicles, brain, heart, and uterus, with a particular role in skin/lipid homeostasis and possible influence on hair follicle biology[3][2]. Like other sPLA2s, it contributes to the modulation of inflammation by releasing lipid mediators that are precursors of eicosanoids and platelet-activating factor. Overactivity or dysregulation of sPLA2s—including PLA2G2E—has been associated with pathologies such as cardiovascular disease and chronic inflammation[7][6][1]. Specific drugs targeting sPLA2 enzymes have so far failed to achieve clinical use largely due to poor selectivity and resulting safety concerns.
- Other names
- Group IIE secretory phospholipase A2sPLA2-IIEPLA2 group IIEPLA2G2E (gene symbol)
02
Mechanism of action
Inhibition of phospholipase A2 catalytic activity, leading to reduced production of lipid mediators (arachidonic acid, eicosanoids) involved in inflammation
03
Biological functions
Hydrolysis of the sn-2 ester bond of phospholipidsRelease of free fatty acids and lysophospholipidsRegulation of lipid mediator generationModulation of inflammatory responsesSpecialized function in skin and hair follicle lipid metabolism
04
Disease associations
InflammationCardiovascular diseasePotential involvement in skin/hair pathophysiologyPossibly other inflammatory or immune-related disorders
05
Safety considerations
Lack of subtype selectivity is a major therapeutic challenge, causing potential off-target effects with sPLA2 inhibitors, such as interference with physiological lipid metabolismInhibition could disrupt normal homeostasis of lipid mediators, with potential consequences for immunity/inflammation
06
Interacting drugs
No clinically approved, highly selective inhibitors; several sPLA2 inhibitors studied in trials, none marketed due to lack of selectivity
1 more in the full profile.
07
Biomarkers
Increased secreted PLA2 activity can indicate inflammatory statesPLA2G2E itself is not a widely accepted disease biomarker but sPLA2 enzymes are being evaluated for roles in cardiovascular and neuroinflammatory diseases
Beyond the preview
Go deeper on Phospholipase A2 group IIE (PLA2G2E).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phospholipase A2 group IIE (PLA2G2E).